Skip to main content
Smart Investors Daily
RL

OTC · RLFTY

Relief Therapeutics Holding AG

Healthcare · Biotechnology

$0.17

Up+$0.00 (+0.00%)

Updated Oct 10, 2026, 11:41 PM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
48.7M
P/E ratio
-2.14
Dividend yield
0.00%
52-week range
— – —
Volume
2.5K
Avg. volume
712

Price performance · RLFTY

RLFTY price history

1M range · 0 trading sessions · Daily adjusted prices

RLFTY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest RLFTY news

The latest Smart Investors Daily articles mentioning RLFTY.

RLFTY research

Overview

Company profile and research snapshot.

Company profile

RELIEF THERAPEUTICS S/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
RLFTY recent ratings
DateFirmRatingTarget
Sep 3, 2026BAADER EUROPEBuy—
Jun 16, 2026BAADER EUROPEBuy—
Jun 15, 2026BAADER EUROPEBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 7, 2026

MindMaze Therapeutics expands digital neurorehabilitation platform across US and Global markets

MindMaze Therapeutics CEO Zach Henderson joined Steve Darling from Proactive’s OTC studio in New York City to discuss the company’s digital neurotherapeutics platform, its approach to expanding rehabilitation access and its growth strategy in the United States and international markets. Henderson said MindMaze is addressing a growing gap between demand from patients recovering from stroke, spinal cord injury, traumatic brain injury and Parkinson’s disease and the limited availability of neurologists and physical therapists. The company’s platform uses gamified, high-dose and high-intensity training that combines physical and cognitive exercises. The technology can be used in inpatient rehabilitation facilities, outpatient centres and at home, giving patients more opportunities to train outside traditional therapy sessions. Henderson said asynchronous training is an important part of the model, helping overcome the limitations of a traditional one-patient, one-therapist approach. He noted that in various deployments, approximately 80% of training doses have been completed asynchronously, without a therapist present. MindMaze has also introduced an at-home model that can provide patients with a tablet and a small additional device. Therapists remain responsible for designing and overseeing programmes, while patients can complete additional training independently. Reimbursement and commercialisation are also key priorities for the company. Henderson said MindMaze already has two CPT codes in the United States and is pursuing payer coverage in additional markets. Studies underway in France and Switzerland are designed to support reimbursement efforts in those countries. The company is currently active in 13 countries, with Henderson identifying the United States as its largest growth opportunity. As MindMaze expands its commercial footprint, the company is focused on using digital technology to increase access to intensive neurorehabilitation while giving therapists tools to support more patients. #proactiveinvestors #mindmazetherapeutics #six #mmtx #otcqb #mmtzf #Neurorehabilitation #DigitalHealth #Neurotherapeutics #StrokeRecovery #Parkinsons #SpinalCordInjury #TraumaticBrainInjury #Rehabilitation #Healthcare #MedTech #HealthTech #DigitalTherapeutics #PhysicalTherapy #Neurology #USHealthcare #MedicalTechnology #Biotech #HealthcareInnovation

Yahoo · Oct 5, 2026

OTC Markets Group Announces Agenda for Third Annual Global Markets Forum, October 7th & 8th

Two-day hybrid event will feature presentations from European and Canadian public growth companies, executive insights, and one-on-one investor meetingsNEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the third annual Global Markets Forum, taking place October 7–8, 2026, in partnership with Aquis Stock Exchange, BME, Canadian Securities Exchange (CSE), OTC Markets Group, and SIX Swiss Exch

Yahoo · Sep 17, 2026

MindMaze Therapeutics Announces MindMotion Lite to Expand Home-Based Neurorehabilitation

MindMaze Therapeutics (SIX: MMTX), a global leader in scalable precision neurotherapeutics, today announced the launch of MindMotion Lite by the end of 2026. Purpose-built for use in the home, the new solution broadens access to intensive neurorehabilitation and represents a key inflection point in the commercial scale-up of the company's platform.

accessnewswire.com · Oct 29, 2025

Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032

RLF-OD032 demonstrated bioequivalence to KUVAN® Powder Study results support planned 505(b)(2) NDA submission in early 2026 GENEVA, SWITZERLAND / ACCESS Newswire / October 29, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced positive results from its pivotal bioequivalence clinical study evaluating RLF-OD032, Relief's innovative and highly concentrated liquid formulation of sapropterin dihydrochloride, for the treatment of phenylketonuria (PKU). The pivotal study achieved its primary pharmacokinetic endpoints, demonstrating that RLF-OD032 is bioequivalent to KUVAN ® Powder, the reference listed drug, as defined by the U.S. Food and Drug Administration.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.